The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets

References

• Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95–108
   PubMed Web of Science ®Google Scholar
• Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: A source of antiangiogenic agents for cancer treatment?. J Natl Cancer Inst 2003; 95: 1660–1673
   PubMedGoogle Scholar
• Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187–2190
   PubMed Web of Science ®Google Scholar
• Salgado R, Benoy I, Dirix L, Vermeulen P, Van Marck E. Importance of platelets in VEGF-mediated angiogenesis in tumors. FEBS Lett 2002; 520: 182
   Google Scholar
• Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549–580
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 2008; 14: 3070–3076
   PubMed Web of Science ®Google Scholar
• Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19: 181–190
   PubMed Web of Science ®Google Scholar
• Italiano JE, Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227–1233
   PubMed Web of Science ®Google Scholar
• Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005; 102: 216–220
   PubMed Web of Science ®Google Scholar
• Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096–2104
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost 1999; 82: 353–356
   PubMed Web of Science ®Google Scholar
• Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879–887
   PubMed Web of Science ®Google Scholar
• Graff J, Klinkhardt U, Schini-Kerth VB, Harder S, Franz N, Bassus S, Kirchmaier CM. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther 2002; 300: 952–957
   PubMed Web of Science ®Google Scholar
• Ma L, Hollenberg MD, Wallace JL. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol 2001; 134: 701–704
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004; 30: 5–20
   PubMed Web of Science ®Google Scholar
• Grignani G, Jamieson GA. Platelets in tumor metastasis: Generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential. Blood 1988; 71: 844–849
   PubMed Web of Science ®Google Scholar
• Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemostasis 1978; 40: 89–102
   Google Scholar
• Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: Absence of role for platelet-derived ADP. Am J Hematol 1981; 11: 367–378
   Google Scholar
• Madsen NJ, Holmes CE, Serrano FA, Sobel BE, Schneider DJ. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Am J Cardiol 2007; 100: 722–727
   PubMedGoogle Scholar
• Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ, et al. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60: 2898–2905
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340–345
   PubMed Web of Science ®Google Scholar
• Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: Interindividual variation and increased platelet secretion. Haematologica 2001; 86: 192–198
   Google Scholar
• Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84: 203–207
   Google Scholar
• Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95: 75–82
   Google Scholar
• Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277–300
   PubMed Web of Science ®Google Scholar
• Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: Significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343–350
   PubMed Web of Science ®Google Scholar
• Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovas Res 2004; 63: 226–235
   PubMed Web of Science ®Google Scholar
• Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost 2005; 31: 150–161
   PubMed Web of Science ®Google Scholar
• Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 1998; 275: 1054–1061
   PubMed Web of Science ®Google Scholar
• Cicha I, Garlichs CD, Daniel WG, Goppelt-Struebe M. Activated human platelets release connective tissue growth factor. Thromb Haemostasis 2004; 91: 755–760
   PubMed Web of Science ®Google Scholar
• Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release. P Natl Acad Sci USA 2001; 98: 6470–6475
   PubMed Web of Science ®Google Scholar
• Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost 2007; 5: 2009–2016
   PubMed Web of Science ®Google Scholar
• Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J, Eckstein R. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem 2005; 51: 2365–2368
   Google Scholar
• Madsen NJ, Holmes CE, Serrano FA, Sobel BE, Schneider DJ. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. Am J Cardiol 2007; 100: 722–727
   PubMedGoogle Scholar
• Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Sem Thromb Hemostasis 2005; 31: 150–161
   PubMed Web of Science ®Google Scholar
• Rendu F, Brohard-Bohn B. The platelet release reaction: Granules' constituents, secretion and functions. Platelets 2001; 12: 261–273
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: Further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20: E101–E106
   PubMed Web of Science ®Google Scholar
• Quinton TM, Murugappan S, Kim S, Jin J, Kunapuli SP. Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. J Thromb Haemost 2004; 2: 978–984
   PubMed Web of Science ®Google Scholar
• Iyengar S, Rabbani LE. Beyond platelet inhibition: Potential pleiotropic effects of ADP-receptor antagonists. J Thromb Thrombolys 2009; 27: 300–306
   Google Scholar